Cigna Corporation (CI) Earnings
Cigna Corporation is expected to report next earnings on October 29, 2026 (in NaN days), with a consensus EPS estimate of $7.49. CI has beaten EPS estimates in 10 of its last 12 reported quarters (average surprise +2.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 30, 2026 | $7.61 | $7.78 | +2.2% | $71.7B | +1.9% |
| Apr 30, 2026 | $7.59 | $7.79 | +2.6% | $68.5B | +2.7% |
| Feb 5, 2026 | $7.86 | $8.08 | +2.8% | $72.5B | +2.6% |
| Oct 30, 2025 | $7.64 | $7.83 | +2.4% | $69.7B | +2.6% |
| Jul 31, 2025 | $7.16 | $7.20 | +0.6% | $67.2B | +5.8% |
| May 2, 2025 | $6.36 | $6.74 | +5.9% | $65.5B | +8.0% |
| Jan 30, 2025 | $7.84 | $6.64 | -15.3% | $65.7B | +3.7% |
| Oct 31, 2024 | $7.25 | $7.51 | +3.6% | $62.8B | +5.8% |
| Aug 1, 2024 | $6.42 | $6.72 | +4.6% | $60.5B | +4.2% |
| May 2, 2024 | $6.21 | $6.47 | +4.1% | $55.4B | -1.4% |
| Feb 2, 2024 | $6.51 | $6.79 | +4.3% | $51.1B | +4.5% |
| Nov 2, 2023 | $6.65 | $6.77 | +1.9% | $49.0B | +1.9% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · July 30, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Core Business Performance and Alignment * The company delivered strong second quarter 2026 results with both business segments exceeding expectations, driven by strategic alignment with key healthcare market needs: affordability, personalized customer experiences, and data-driven clinical programs to improve population health. * Total company second quarter 2026 revenues hit $71.7 billion, with adjusted earnings per share (EPS) of $7.78. - AI and Technology Innovation * Management is prioritizing meaningful, customer-centric AI investments that improve outcomes, reduce friction, and lower costs, rather than standalone tech initiatives. * Key AI-enabled launches include Pharmacy Forward, which cuts average time to start specialty therapy in half and reduces clinician documentation time by up to 50%, and expanded AI-powered care coordination that will support 20% more customers with emerging complex chronic conditions, reducing average annual medical costs by $2,000 and cutting avoidable inpatient stays by 42% for engaged customers. - Strategic Product Initiatives * The new rebate-free Signature pharmacy benefit model is on track for introduction to Cigna Healthcare's fully insured plans in 2027, with a broader market launch scheduled for 2028. Early client interest is strong, and the 2027 selling season for pharmacy benefit services is one of the strongest in recent years, with total new business secured already exceeding the prior two selling seasons combined. * Cigna Healthcare continues to expand behavioral health offerings, including AI-powered provider matching that reduces costs and lower-acity options like Headspace that expand access and encourage early intervention. - Capital Management * As of June 30 2026, the debt to capitalization ratio was 42.8%, with management targeting an end-of-year ratio closer to 40%. The company repurchased 900,000 shares for $250 million in the second quarter, and management views share repurchases as an attractive use of capital alongside disciplined debt paydown.
Guidance
- Full year 2026 adjusted EPS guidance is raised upward from the prior outlook to at least $30.45, reflecting strong first half performance while maintaining a prudent view of the operating environment. - Full year 2026 medical care ratio (MCR) guidance is maintained unchanged. Third quarter MCR is expected to be slightly above the second quarter level, consistent with historical seasonality. - Full year 2026 operating cash flow is expected to hit approximately $9 billion, and remains back half-weighted consistent with historical patterns. - The second half 2026 adjusted EPS is expected to be split roughly evenly between the third and fourth quarters. - 2027 enterprise EPS growth is still expected to fall within the prior guided range of 10% to 14%, with formal 2027 segment-level guidance to be provided in the fourth quarter 2026 call. - The Signature pharmacy benefit model is still expected to deliver long-term margins of approximately 4%, consistent with legacy PBM offerings, and remains on track for scaled launch in 2028.
Segment performance
Evernorth Health Services: Second quarter 2026 revenues grew 6% year-over-year to $61.5 billion, with total pre-tax adjusted earnings of $1.7 billion, slightly ahead of expectations. Within Evernorth: 1) Specialty and care services: Pre-tax adjusted earnings grew 22% year-over-year, driven by higher-than-expected adoption of specialty generics and biosimilars, operating efficiencies, and contributions from the Shields Health Solutions investment. 2) Pharmacy benefit services: Pre-tax adjusted earnings were $609 million, down year-over-year as expected, due to the impact of large client contract renewals/extensions and investments for the transition to the new rebate-free Signature model. Cigna Healthcare: Second quarter 2026 revenues grew 10% year-over-year to $11.8 billion, with pre-tax adjusted earnings of $1.3 billion, ahead of expectations. The medical care ratio (MCR) was 84.5%, slightly better than expectations, driven by strong performance in the U.S. employer business and slightly favorable medical cost trends (lower outpatient and surgical spend). Medical membership grew year-to-date, and the segment achieved 17% pre-tax adjusted earnings growth year-over-year.
Risks & headwinds
- Continued economic pressures, geopolitical uncertainty, and persistently elevated overall healthcare cost trends create headwinds for affordability and margins. - The Independent Dispute Resolution (IDR) mechanism for surprise billing is seeing unsustainable volume, with most decisions and settlement values favoring providers, leading to wasteful industry-wide spending that exacerbates affordability challenges, though Cigna's impact has remained within planning assumptions to date. - High prices for brand prescription drugs (including GLP-1s for weight management) continue to strain plan affordability, leading more clients to restrict coverage and creating modest headwinds for pharmacy benefit services revenue. - Stranded overhead is expected after the full exit from the ACA individual exchange business at the end of 2026, though the full impact is still being evaluated. - All forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from current expectations.
Analyst Q&A
Q: How is Evernorth's earnings growth progression expected to develop in the back half of 2026, given the shift in earnings from biosimilar adoption between segments? /
A: Second quarter 2026 saw faster-than-expected adoption of specialty generics and biosimilars, which drove outperformance in specialty and care services, partially offset by softer results in pharmacy benefit services, alongside modestly lower-than-expected GLP-1 volume growth. The strong second quarter benefit from accelerated adoption is not expected to repeat at the same magnitude in the second half, though specialty and care will still see strong tailwinds built into the original full year guidance. Overall, offsetting dynamics across the two Evernorth sub-segments leave the overall full year Evernorth outlook unchanged, and the enterprise's overall strength allowed the company to raise full year adjusted EPS guidance.
Q: What is the status of the Signature PBM transition, including progress with stakeholders like pharma and network pharmacies, and what is the expected long-term growth and margin profile for the PBM business? /
A: The Signature model is aligned with upcoming 2028 CAA regulation and goes beyond minimum requirements to deliver greater transparency and affordability. Conversations with pharma manufacturers and network pharmacies have been positive and productive to date. The model is on track for use by Cigna Healthcare's fully insured book in 2027 and broad scaling in 2028, and is expected to deliver long-term margins of approximately 4%, matching legacy PBM product levels. Long-term PBM growth of 2% to 4% remains the baseline expectation, and enterprise EPS growth for 2027 is still expected to hit the 10% to 14% prior range.
Q: What is the outlook for growth in Evernorth's hospital and health system specialty services, following the Shields Health Solutions investment? /
A: The overall U.S. specialty pharmacy market is a nearly $500 billion total addressable market with high single-digit secular growth, with 40% of that market consisting of provider-administered drugs, where Evernorth historically had a small footprint. Shields is the clear leader in management services for health system-owned specialty pharmacies, serving over 80 large health systems across 50 states. Growth opportunities come from overall market growth, increasing penetration of third-party management services as the market matures, and cross-selling combined capabilities to existing clients, and the company will continue investing in this high-growth segment.
Q: What is driving more employer decisions to restrict GLP-1 coverage for weight management, and what is the impact on Cigna's results? /
A: High net costs of GLP-1s for weight management continue to strain employer plan affordability, leading more clients to restrict coverage, matching the dynamic that led Cigna to eliminate GLP-1 weight management coverage for its own employee plan (while retaining coverage for diabetes). This dynamic has created a modest headwind to 2026 results, which was more than offset by second quarter strength in specialty care. Cigna offers a full range of coverage options for clients, and the market approach to GLP-1 coverage will continue to evolve as drug pricing changes.